Fig. 4: Therapeutic efficacy of 2G1 against SARS-CoV-2 variants in transgenic mice. | Cell Discovery

Fig. 4: Therapeutic efficacy of 2G1 against SARS-CoV-2 variants in transgenic mice.

From: Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD

Fig. 4

a High permissive AC70 human ACE2 transgenic mice were challenged with 100 LD50 of SARS-CoV-2 WA1/2020, Beta- or Delta- variants, followed by 20, 6.7, or 2.2 mg/kg of 2G1 treatment (n = 14). A 12-day clinical observation was implemented. b Body weight change of mice. c Clinical illness of mice was assessed based on a standardized 1 to 4 grading system that describes the clinical wellbeing of mice. d Mortality of mice. Mice were monitored until 12 dpi unless the designed endpoint was reached. e Viral load in lung and brain tissues. Data are shown as means ± SD. Vhcl vehicle control, p.i. post infection.

Back to article page